Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 19 Show results per page	View Search Criteria \| Help With Results

Last Modified: 1/29/2008 First Published: 12/8/2006


1.		Phase III/IV Randomized Study of Risk-Adapted Therapy Comprising Observation Only, Combination Chemotherapy, Radiotherapy, and/or Autologous Stem Cell Transplantation in Younger Patients With Neuroblastoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV, Phase III				Treatment				Active				21 and under				Other				GPOH-NB2004 EU-20661, NCT00410631

Last Modified: 1/2/2008 First Published: 2/1/2002


2.		Phase III Randomized Study of Induction Chemotherapy With or Without Filgrastim (G-CSF) Followed By Surgery, Myeloablative Therapy, and Radiotherapy With Isotretinoin With or Without Monoclonal Antibody Ch14.18 in Patients With High-Risk Neuroblastoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				1 to 20 at diagnosis				Other				SIOP-EUROPE-HR-NBL-1 ESIOP, EU-20148, NCT00030719

Last Modified: 1/14/2009 First Published: 10/21/2006


3.		Phase III Randomized Study of Standard Chemoradiotherapy With or Without Carboplatin Followed by Standard Maintenance Therapy With or Without Isotretinoin and Continuation Therapy With Isotretinoin Versus No Continuation Therapy in Pediatric Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				3 to 21				NCI				COG-ACNS0332 ACNS0332, NCT00392327

Last Modified: 1/14/2009 First Published: 7/6/2007


4.		Phase III Study of Response- and Biology-Based Combination Chemotherapy and Surgery With or Without Isotretinoin in Young Patients With Intermediate-Risk Neuroblastoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				12 and under				NCI				COG-ANBL0531 ANBL0531, NCT00499616

Last Modified: 1/14/2009 First Published: 12/3/2007


5.		Phase III Randomized Study of Single Versus Tandem Myeloablative Consolidation Therapy Followed by Peripheral Blood Stem Cell Transplantation in Young Patients With High-Risk Neuroblastoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Biomarker/Laboratory analysis, Treatment				Active				30 and under				NCI				COG-ANBL0532 ANBL0532, NCT00567567


6.		Multicentric Study Comparison Between Erythropoietin and Erythropoietin Associated to Differentiating Therapy With Acid 13-Cis-Retinoic and Dihydroxyvitamin D3 in Myelodysplastic Syndromes Without Excess of Blasts

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other				EPO2006-AISSM04 2006-006482-16, NCT00804050

Last Modified: 8/23/2006 First Published: 5/5/2006


7.		Phase I/II Study of Vorinostat (SAHA) in Combination With Isotretinoin in Patients With Advanced Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				21 and over				NCI				NYWCCC-0511008257 6896, NCI-6896, NCT00324740


8.		Vorinostat, Isotretinoin and Carboplatin in Adults With Recurrent Glioblastoma Multiforme (GBM)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				2006-0709 NCT00555399

Last Modified: 6/2/2008 First Published: 2/5/2008


9.		Phase I/II Study of Cytoreduction Therapy Comprising High-Dose Cytarabine and Mitoxantrone Hydrochloride in Patients With Juvenile Myelomonocytic Leukemia Undergoing a Second Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Residual Disease

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				Juvenile				NCI				UMN-1999LS032 UMN-1999LS032, UMN-MT1999-08, NCT00609739


10.		A Phase I/Ii Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells After High-Dose Chemotherapy And Autologous Stem Cell Rescue In Patients With High Risk Neuroblastoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				Under 21				Other				22053 NCT00703222

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute